LONDON, May 27, 2014 /PRNewswire/ --
On Friday, May 23, 2014, the NASDAQ Composite ended at 4,185.81, up 0.76%, the Dow Jones Industrial Average finished the day 0.38% higher at 16,606.27, and the S&P 500 closed at 1,900.53, up 0.42%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 681.33, up 0.08%, and the index has advanced 2.63% in the previous one month. Investor-Edge has initiated coverage on the following equities: Becton, Dickinson and Company (NYSE: BDX), Insulet Corporation (NASDAQ: PODD), Antares Pharma Inc. (NASDAQ: ATRS) and Haemonetics Corp. (NYSE: HAE). Free technical research on BDX, PODD, ATRS and HAE can be downloaded upon signing up at:
http://www.investor-edge.com/3043-register
On Friday, Becton Dickinson and Co.'s stock edged 0.14% higher, to close the day at $115.70. The stock recorded a trading volume of 0.41 million shares, below its three months average volume of 0.81 million shares. The stock oscillated between $115.30 and $116.09 during the session. Over the past one month and over the last three months, Becton Dickinson and Co.'s shares have gained 2.79% and 1.02%, respectively. Additionally, the stock has gained 4.72% since start of this year. The stock is trading above its 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $114.89 is greater than its 200-day moving average of $108.59. Additionally, the stock traded at a PE ratio of 23.82 and has a Relative Strength Index (RSI) of 52.36. Sign up today to read free research on BDX at:
http://www.investor-edge.com/3043-BDX-27May2014.pdf
On Friday, Insulet Corp.'s stock traded between $34.32 and $35.60 before ending the session 0.60% higher at $35.10. Insulet Corp.'s stock reported a trading volume of 0.52 million shares, below its three months average volume of 0.69 million shares. Although, Insulet Corp.'s shares have gained 4.84% in the previous three trading sessions, it has declined 12.62% in the last one month and 5.39% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $41.45 and $39.16, respectively. Further, shares of the company have an RSI of 41.29. Sign up today to read free research on PODD at:
http://www.investor-edge.com/3043-PODD-27May2014.pdf
Share in Antares Pharma Inc. finished the Friday's session 0.33% lower at $3.00. A total of 0.63 million shares were traded, which was below to its three months average volume of 1.67 million shares. The stock moved between $2.96 and $3.03 during the session. Antares Pharma Inc.'s shares have advanced 2.39% in the last three trading sessions and 4.90% in the past one month. However, the stock has declined 32.90%, since start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.03 is greater than its 50-day moving average of $3.22. Antares Pharma Inc.'s stock has an RSI of 48.71. Sign up today to read free research on ATRS at:
http://www.investor-edge.com/3043-ATRS-27May2014.pdf
On Friday, Haemonetics Corp.'s stock recorded a trading volume of 0.61 million shares, lower than its three months average volume of 0.66 million shares. The stock ended the day at $34.62, which was 0.17% below its previous day's closing of $34.68, and registered an intraday range of $34.35 and $34.89. Haemonetics Corp.'s shares have advanced 3.59% in the last three trading sessions and 4.12% in the previous one month. However, the stock has lost 17.83% since beginning of this year. Shares of the company traded at a PE ratio of 20.19. The company's stock is trading above its 50-day moving average of $33.24, while the 50-day moving average is below its Haemonetics Corp.'s 200-day moving average of $38.56. Furthermore, shares of the company have an RSI of 63.14. Sign up today to read free research on HAE at:
http://www.investor-edge.com/3043-HAE-27May2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
